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OBJECTIVES The purpose of this study was to determine whether atrial expression of the extracellular
signal-regulated kinases Erk1/Erk2 and of the angiotensin-converting enzyme (ACE) is
altered in patients with atrial fibrillation (AF).
BACKGROUND Recent studies have demonstrated that atrial fibrosis can provide a pathophysiologic substrate
for AF. However, the molecular mechanisms responsible for the development of atrial fibrosis
are unclear.
METHODS Atrial tissue samples of 43 patients undergoing open heart surgery were examined. Seventeen
patients had chronic persistent AF ($6 months; CAF), 8 patients had paroxysmal AF (PAF)
and 18 patients had no history of AF. Erk expression was analyzed at the mRNA
(quantitative reverse transcription polymerase chain reaction), the protein (immunoblot
techniques) and atrial tissue (immunohistochemistry) levels. Erk-activating kinases
(MEK1/2) and ACE were analyzed by immunoblot techniques.
RESULTS Increased amounts of Erk2-mRNA were found in patients with CAF (75 6 20 U vs. sinus
rhythm: 31 6 25 U; p , 0.05). Activated Erk1/Erk2 and MEK1/2 were increased to more
than 150% in patients with AF compared to patients with sinus rhythm. No differences
between CAF and PAF were found. The expression of ACE was three-fold increased during
CAF. Amounts of activated Erk1/Erk2 were reduced in patients treated with ACE
inhibitors. Patients with AF showed an increased expression of Erk1/Erk2 in interstitial cells
and marked atrial fibrosis.
CONCLUSIONS An ACE-dependent increase in the amounts of activated Erk1/Erk2 in atrial interstitial cells
may contribute as a molecular mechanism for the development of atrial fibrosis in patients
with AF. These findings may have important impact on the treatment of AF. (J Am Coll
Cardiol 2000;35:1669–77) © 2000 by the American College of Cardiology
Atrial fibrillation (AF), the most common arrhythmia in
clinical practice, is a potential cause of thromboembolic
events (1,2). Several studies have shown that AF induces
significant changes of the electrophysiologic properties of
atrial myocytes and causes alterations in the structure of the
atrial tissue (3–7). In contrast to most AF animal models,
patchy necrosis or fibrosis exist in atrial tissue of patients
with idiopathic AF (8). Whether atrial fibrosis induces AF
or is a consequence of AF is still unknown. Li et al. (9)
showed that atrial fibrosis in the failing animal heart
provides a pathophysiologic substrate for AF. Atrial fibrosis
was associated with circumscribed electrophysiologic inho-
mogeneities of the atria allowing the induction of prolonged
episodes of AF. The development of atrial fibrosis, there-
fore, may explain the occurrence of AF in patients with
structural heart disease. Alterations of the atrial tissue
architecture may also contribute to the mechanical dysfunc-
tion of the atria (6,7,10).
The molecular basis for the development of atrial fibrosis
in patients with AF is still a matter of debate. Its under-
standing, however, could have an important therapeutic
impact. The purpose of our study was to assess the role of
extracellular signal-regulated kinases (Erk1 and Erk2) and
its activating mechanisms in patients with and without AF.
Erk1 and Erk2 belong to the subfamilies of mitogen-
activated protein kinases (MAPK) (11,12). Activation of
the Erk pathway by G protein-coupled receptor agonists
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like angiotensin II (Ang II) induces cellular differentiation
processes and an activation of fibroblasts that causes the
development of interstitial fibrosis (11–14). Therefore, it is
important to find out whether AF is associated with an
activation of the erk pathway in the human atrium. Atrial
expression and activation of Erk were studied at the mRNA,
the protein and tissue levels in patients with chronic or
paroxysmal AF. The expression of phosphorylated Erk-
activating kinases (MEK1/2) and the atrial angiotensin-
converting enzyme (ACE) was also evaluated.
METHODS
Patients. All experiments were performed in compliance
with the relevant laws and institutional guidelines. After
written informed consent, right atrial appendages were
obtained from patients undergoing cardiac bypass surgery or
valve replacement (mitral valve and/or aortic valve replace-
ment). Appendages were obtained from 17 patients with
chronic AF (defined as persistent AF $ 6 months; CAF), 8
consecutive patients with documented episodes of paroxys-
mal AF (3 6 2 AF episodes per month; PAF) and from 18
patients without a history of AF. Four patients with PAF
were in sinus rhythm and the remainder had AF at the time
of surgery. All 43 patients were in New York Heart
Association class II. None of them had received amiodarone
prior to surgery. The clinical characteristics are shown in
Table 1. Expression and activation of protein kinases
(MEK1/2 and Erk1/Erk2) as well as expression of the ACE
were analyzed in matched groups of patients (age, severity of
cardiac and noncardiac diseases, ACE inhibitor therapy)
with sinus rhythm (SR) and CAF. In patients with PAF,
the amounts of activated MEK1/2 as well as Erk1/Erk2
expression/activation were determined.
RNA-isolation. Samples of human atrial appendages were
obtained during the surgical procedures and rapidly frozen
in liquid nitrogen and stored at 2192°C for further analysis.
Total RNA was prepared as described by Chomczynski and
Sacchi (15). About 200 mg of tissue was homogenized on
ice in 2 ml of TRIZOL (Gibco BRL; Karlsruhe, Germany)
using an UltraTurrax. After the addition of 400 ml of
chloroform, the samples were vortexed and centrifuged at
4°C and 14,000 g for 15 min. Total RNA was precipitated
from the aqueous phase by the addition of 1 volume of
ice-cold isopropanol. The RNA was dissolved in 0.1%
sodium dodecyl sulfate (SDS) and reprecipitated by the
addition of 1/10 volume 5 mol/liter ammonium acetate, at
a pH of 4.8, and 2.5 volumes of ice-cold ethanol. Contam-
inating DNA was removed by DNase I digestion (Boehr-
inger Mannheim; Mannheim, Germany; 20 U/50 ml reac-
tion, 30 min at 37°C). Subsequently, RNA was subjected to
a second round of purification by means of the RNeasy Mini
Kit (Qiagen; Hilden, Germany), and the resulting RNA
was quantified spectrophotometrically using a GeneQuant
(Pharmacia LKB, Freiburg, Germany). The RNA was
aliquoted and stored ethanol-precipitated at 280°C until
use.
Reverse transcription. In each case, 1 mg of total RNA
was transcribed in a final volume of 20 ml by 20 U of AMV
reverse transcriptase (Stratagene; Heidelberg, Germany) in
the supplied buffer with the addition of 0.5 mmol/liter
dNTP, 10 mmol/liter random hexanucleotides (Boehringer
Mannheim) and 50 U of placenta RNase inhibitor (Am-
bion; Austin, Texas) during a 1-h incubation at 37°C. The
enzymes were inactivated by a 10-min incubation at 65°C,
and the reaction mixture was kept frozen at 270°C until
enzymatic amplification.
Quantitative polymerase chain reaction (PCR). Quanti-
tative PCR was performed in 10-ml reaction capillaries
using the Lightcycler LC24 (Idaho Technology; Boston,
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
AF 5 atrial fibrillation
Ang II 5 angiotensin II
CAF 5 chronic persistent AF $6 months
Erk 5 extracellular signal-regulated kinase
JNK 5 c-Jun N-terminal kinase
MAPK 5 mitogen-activated protein kinase
MEK 5 Erk-activating kinase
PAF 5 paroxysmal AF
RT-PCR 5 reverse transcription polymerase chain
reaction
SDS 5 sodium dodecyl sulfate
SR 5 sinus rhythm
Table 1. Patient Characteristics
SR PAF CAF
Subjects (n) 18 8 17
Age (yr) 63 6 10 67 6 10 66 6 6
Gender (m/f) 12/6 7/1 12/5
History AF (mo) — 10 6 6 53 6 40
CAD (%) 67 (12) 63 (5) 59 (10)
MI (%) 33 (6) 50 (4) 29 (5)
AVD (%) 28 (5) 25 (2) 24 (4)
MVD (%) 22 (4) 13 (1) 18 (3)
LVEF (%) 54 6 15 47 6 15 55 6 12
LAD (cm) 4.3 6 0.8 4.6 6 0.2 5.0 6 0.3*
Hypertension (%) 44 (8) 50 (4) 47 (8)
Diabetes (%) 33 (6) 25 (2) 35 (6)
ACE inhibitors (%) 61 (11) 75 (6) 59 (10)
Beta-adrenergic
blocking agents (%)
44 (8) 38 (3) 41 (7)
Calcium antagonists (%) 28 (5) 25 (2) 41 (7)
Digitalis (%) 22 (4) 38 (3) 47 (8)
*p , 0.05 versus sinus rhythm.
ACE 5 angiotensin-converting enzyme; AF 5 atrial fibrillation; AVD 5 aortic
valve disease requiring valve replacement; CAD 5 coronary artery disease; CAF 5
chronic AF; LAD 5 left atrial diameter; LVEF 5 left ventricular ejection fraction;
MI 5 history of myocardial infarction; MVD 5 mitral valve disease requiring valve
replacement; PAF 5 paroxysmal AF; SR 5 sinus rhythm; numbers in parentheses
represent the absolute number.
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Massachusetts). For the determination of Erk2 mRNA
amounts, a typical 10-ml reaction mixture consisted of 13
reaction mixture with bovine serum albumin (Idaho Tech-
nology), 3 mmol/liter MgCl2, 200 mmol/liter dNTPs, 0.4 U
InViTaq-polymerase (InViTec; Berlin, Germany), 0.2 ml of
a 1:1,000 dilution of SYBR Green I (Molecular Probes; 1 ml
cDNA and 0.5 mmol/liter of the Erk2-specific primers
Erk2-US (59-CATCGCCGAAGCACCATTCAAG)
and Erk2-DS (59-GATAAGCCAAGACGGGCTGG
AG). Initial denaturation at 95°C for 10 s was followed by
40 cycles with denaturation at 95°C of 0.1 s, annealing at
65°C for 3 s, and elongation at 72°C for 16 s. The
fluorescence intensity of the double-strand specific SYBR
Green I, reflecting the amount of formed PCR product, was
read at the end of each elongation step.
Western blotting. About 200 mg of tissue was homoge-
nized directly in 23 RotiLoad (Roth; Karlsruhe, Germany)
using an UltraTurrax. The homogenate was cleared by
ultracentrifugation at 4°C, 100,000 g, 30 min. Protein
contents were determined by using an assay kit (Protein
Assay Kit; Sigma; Heidelberg, Germany). After 5 min,
boiling samples (300 mg each) were applied onto precast 4%
to 12% gradient SDS-polyacrylamide gels (NuPAGE;
Novex Electrophoresis; Frankfurt a.M., Germany) and
separated at 300 V, 15 mA constant using MOPS-SDS
running buffer (Novex). Proteins were transferred onto
nitrocellulose membrane BAS-85 (Schleicher & Schu¨ll;
Goslar, Germany) by means of a semidry blotter (Bio-Rad,
Munich, Germany) (25 V, 2 h, 50 mmol/liter Tris-borate-
buffer, pH 9.0). Membranes were blocked by overnight
incubation in 7.5% (w/v) milk powder in phosphate-
buffered saline solution. The following primary antibodies
were used for immunodetection: rabbit anti-Phospho-p44/
p42 MAP kinase (Thr202/Tyr204) polyclonal, purified Ig
(PhosphoPlus p44/p42 Antibody Kit; New England Bio-
labs; Schwalbach, Germany); rabbit anti-MEK1/2 poly-
clonal, purified Ig (PhosphoPlus MEK1/2 Antibody Kit;
New England Biolabs); mouse anti-ACE monoclonal anti-
body, IgG1 (Chemicon; Hofheim, Germany). Goat-anti-
rabbit-POD or goat-anti-mouse-POD (New England Bio-
labs) and “SuperSignal West Dura Extended Duration
Substrate” (Pierce) were used for chemiluminescence detec-
tion. The resulting images were densitometrically quantified
by using software (RFLP-Scan software; MWG Biotech;
Ebersberg, Germany). The mean relative absorption units
of the group with sinus rhythm were set as control and
compared with the corresponding means of the AF groups.
To avoid artificial variations of individual blots, protein
determination, SDS-polyacrylamide gel electrophoresis,
blotting, immunostaining and chemoluminescence detec-
tion were performed simultaneously in the same batch of
reagents. Densitometric quantification for comparison of
the different groups was done only on blots processed
equally and exposed on the same X-ray film.
Histochemistry and immunohistochemistry. Histochem-
istry and immunohistochemistry were performed in a total
of 22 tissue specimens. Ten specimens were from patients
with sinus rhythm, eight from patients with CAF and the
remaining four samples were obtained from patients with
PAF. Tissue samples were fixed in formalin and embedded
in paraffin. Deparaffinized sections were stained with hema-
toxylin/eosin and Masson trichrome. Immunostaining was
performed with a polyclonal antibody, as specified above,
directed against phosphorylated Erk1/Erk2 (dilution
1:500). Prior to immunostaining, the specimens were pre-
treated with 10 mmol/liter EDTA (2 3 10 min, 450 W
microwave oven). Immunoreaction was visualized by the
avidin-biotin-complex method applying a Vectastain ABC-
alkaline phosphatase-kit (CAMON; Wiesbaden, Ger-
many). Neufuchsin served as chromogen. The specimens
were counterstained with hematoxylin. The specificity of
immunostaining was controlled by omitting the primary
antibody.
Statistical analysis. Differences in the amounts of Erk2-
mRNA, activated MEK1/2 and activated Erk1/Erk2
among the three groups of patients were evaluated using
one-way analysis of variance. A t test with Bonferroni
correction was used to evaluate the significance of differ-
ences between individual mean values. The unpaired Stu-
dent t test was used to compare ACE expression in patients
with SR and CAF as well as amounts of activated Erk1/
Erk2 in patients with and without ACE inhibitor therapy.
Linear regression was used for correlation between the
amounts Erk2-mRNA or activated Erk2 and AF duration
as well as ACE expression and amounts of activated Erk1/2
and MEK1/2. All values are expressed as mean 6 SD and
a p value ,0.05 was considered to be statistically significant.
RESULTS
The baseline patient characteristics are shown in Table 1.
The severity of the underlying heart diseases and noncardiac
diseases was not different between the groups. The left atrial
diameter was increased in patients with CAF compared to
patients with SR.
Erk2 gene expression. The amount of Erk2 mRNA was
significantly increased in patients with CAF (75.8 6
19.6 U; n 5 12) compared to patients with SR (30.7 6
24.9 U; n 5 12; p , 0.05). Patients with PAF had
intermediate Erk2 mRNA levels (50.0 6 29.5 U; n 5 8).
The differences in Erk2 mRNA levels between PAF and
patients with SR did not reach statistical significance (Fig.
1). There was no correlation between AF duration and Erk2
mRNA content (r 5 0.18; p 5 NS) in patients with CAF.
Phosphorylated Erk1 and Erk2 (Pp44/Pp42). The
tyrosine-phosphorylated forms of Erk1 (Pp44) and Erk2
(Pp42) were significantly increased in atrial tissue of patients
with CAF (Erk1: 249 6 55%; Erk2: 301 6 48%; n 5 11;
p , 0.01) as well as PAF (Erk1: 193 6 43%; Erk2: 255 6
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52%; n 5 8; p , 0.01) compared to patients in SR (Erk1:
100 6 21%; Erk2: 100 6 22%; n 5 11) (Fig. 2). The
differences between CAF and PAF were not significant.
Similar to the expression of Erk2 mRNA, amounts of
activated Erk2 did not correlate with AF duration (r 5 0.2;
p 5 NS). Both the amounts of activated Erk1 and Erk2
were reduced in patients with SR treated with ACE
inhibitors at the time of surgery (Erk2: 158 6 46 U; n 5 9
vs. 334 6 67 U; n 5 7; p , 0.02; Erk1: 58 6 61 U vs.
135 6 63 U; p , 0.05) (Fig. 3). Linear regression analysis
showed a trend toward an inverse relation between ACE
expression and the amount of activated Erk1/2 (r 5 20.3;
p 5 NS) and between ACE expression and the amount of
activated MEK1/2 (r 5 20.3; p 5 NS) in this group of
patients. There were no other differences in clinical param-
eters (age, ejection fraction, severity of heart disease, etc.)
among these 16 patients with and without ACE inhibitors.
Reduced Erk2 activity was also found in patients with CAF
who were treated with ACE inhibitors (234 6 79 U; n 5 9
vs. 464 6 279 U; n 5 7; p , 0.05). Slight changes in the
amounts of activated Erk1 did not reach statistical signifi-
cance (73 6 29 U vs. 125 6 87 U; p 5 NS). No linear
relation between ACE expression and activated Erk1/2
could be demonstrated in patients with CAF (r 5 0.2; p 5
NS).
Expression of Erk-activating kinases (MEK1/2). The
relative amount of activated (phosphorylated) Erk-
activating kinases (MEK1/2) was increased during CAF
(MEK1/2: 168 6 21%; n 5 11; p , 0.05) as well as PAF
(MEK1/2: 176 6 14%; n 5 8; p , 0.05) compared with SR
(100 6 7%; n 5 11). Comparable to the amounts of
activated Erk1/Erk2, the differences in the amounts of
activated MEK1/2 in patients with CAF or PAF were not
significant either (Fig. 2).
Expression of ACE. The expression of ACE was deter-
mined in seven patients with CAF and in seven matched
patients with SR. None of the patients had been treated
with ACE inhibitors before surgery. The expression of
ACE was found to be substantially increased in patients
with CAF (ACE: 297 6 44%; p , 0.01) compared with
patients in SR (Fig. 4). The expression of ACE correlated
with the amount of activated Erk1 (r 5 0.6; p 5 0.06) and
Erk2 (r 5 0.4; p 5 NS) in patients with CAF. The
correlation between ACE expression and activated
MEK1/2 was r 5 0.3 (p 5 NS). Similarly, only weak linear
relations between ACE expression and amounts of activated
Erk1/2 (r 5 0.4; p 5 NS) as well as ACE expression and
activated MEK1/2 (r 5 0.3; p 5 NS) were found in patients
with SR.
Histochemistry and immunohistochemistry. The immu-
nohistochemical distribution of activated Erk1/Erk2 in the
atria showed similar staining patterns in patients with (n 5
12) or without AF (n 5 10): Erk1/Erk2 was found in the
cytoplasm of interstitial cells (most likely representing fi-
broblasts), vascular endothelial cells and pericardial fat cells.
The overall number of immunoreactive cells, particularly of
interstitial cells (Fig. 5), and the intensity of immunostain-
ing appeared to be increased in the atria of patients with AF
compared to those without AF. No significant difference
was found between PAF and CAF. Few atrial myocytes
were immunoreactive for Erk1/2 only in two cases of CAF
(one patient with coronary artery disease, one patient with
aortic valve disease). However, antigenicity of intracellular
proteins was not affected by the fixation procedure as
demonstrated by intense immunostaining of myocytes with
antidesmin (not shown) or antimyoglobin (Fig. 5C).
Extensive interstitial fibrosis, evidenced by a Masson
trichrome stain, was found in patients with AF (Fig. 5D).
The amount of fibrosis exceeded impressively the degree of
fibrosis seen in patients without AF.
DISCUSSION
Main findings. To the best of our knowledge, this study
discusses for the first time a molecular mechanism being
responsible for the development of atrial fibrosis in patients
with AF. Atrial tissue of patients with CAF or PAF showed
increased levels of phosphorylated (activated) Erk1 and
Erk2. Increased amounts of phosphorylated Erk1 and Erk2
presumably result from an increased activity of Erk-
activating kinases MEK1/2. The amounts of activated
Erk1/Erk2 were not related to the arrhythmia duration as
evidenced by similar levels of phosphorylated Erk1/Erk2 in
patients with CAF and PAF. Besides the enhanced levels of
activated Erk2, the expression of Erk2 mRNA and the
expression of ACE were increased during CAF. The
amount of activated Erk2 was reduced in patients who were
treated with ACE inhibitors. Immunohistologic study
showed activated Erk1/Erk2 predominantly in interstitial
cells, the capillary endothelium and in the atrial fat tissue
Figure 1. Atrial expression of Erk2 mRNA in patients with SR
(n 5 12), in PAF (n 5 8) and during CAF (n 5 12). Erk2 mRNA
was increased in patients with CAF (221 6 189%). The increase
of Erk2 mRNA levels in PAF was not significant (146 6 86%
compared with SR). Asterisk: p , 0.05 versus SR.
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regardless of the underlying atrial rhythm. However, the
intensity of Erk immunostaining was increased in interstitial
cells of patients with AF and these patients showed marked
atrial fibrosis.
Mechanisms for increased ACE and Erk2 expression.
Growth signals received by cell membranes are transmitted
to the nucleus through an intricate network that consists of
a complex array of protein-protein interactions generally
governed by phosphorylation (11,12). After binding to its G
protein-coupled receptor, Ang II activates Erk1/Erk2
through well described signaling pathways (12,13,16,17).
During the final step of this cascade, Erk1/Erk2 are phos-
phorylated by MEK1/2. Phosphorylated Erks stimulate the
phosphorylation and activation of transcription factors such
as Fos. This triggers the expression of genes encoding
contractile, structural and cell-cycle regulatory proteins
(16,18). Due to these effects, Erk1/Erk2 are known to be
involved in cellular growth, proliferation and differentiation
processes (11,13,14). Yamazaki et al. (13,16) showed that
mechanical stretch can induce cardiac hypertrophy by Ang
II- or endothelin I-dependent mechanisms using activation
of Erk. They demonstrated in their in vitro experiments that
the activity of MAPK increased within minutes by an Ang
II-dependent mechanism after mechanical stretch had been
applied to cardiac myocytes. In addition to these effects on
myocytes, other studies have shown that Ang II can also
induce, via activation of MAPK such as Erk1/Erk2, prolif-
eration of fibroblasts as well as extracellular matrix protein
accumulation (17,18). It has been reported that the effects of
Ang II on cultured myocytes require cardiac fibroblasts in
the culture. Purified cardiac myocytes alone did not respond
to Ang II (19). These reports support the assumption of a
Figure 2. A, Western blots demonstrating atrial expression of phosphorylated Erk-activating kinases (MEK1/2) and phosphorylated
Erk1/Pp44 (upper band) and Erk2/Pp42 (lower band) in patients with SR (n 5 11), with PAF; (n 5 8) and with CAF (n 5 11). B,
Densitometric quantification of Western blots shown in A. MEK1/2, Erk1 and Erk2 activities are shown as relative densitometric
absorption units. Asterisk: p , 0.01 versus SR. Dagger: p , 0.05 versus SR.
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mechanism whereby Ang II induces the release of
fibroblast-derived paracrine factors that trigger the myocar-
dial responses. These findings show that interstitial cells are
a main target for Ang II action in cardiac tissue. Some of the
Ang II-induced effects on the interstitium could be reversed
or blunted by inhibition of the cardiac angiotensin system
(18,20).
Our results indicate that CAF and PAF are indeed
accompanied by increased atrial expression of ACE and
Erk2 as well as elevated levels of activated Erk1/Erk2 and
MEK1/2 in humans. The demonstrated activation of the
MEK-Erk pathway within the atrial interstitium appears as
one molecular mechanism explaining fibrotic changes of the
atrial tissue in patients with AF. Within the intact atria, it
seems indicative that conditions associated with increased
atrial volume and/or filling pressures enhance atrial stretch
and thereby trigger the expression of ACE. This may
stimulate, via Ang II, the activation of Erk1/Erk2 within
interstitial cells. White et al. (21) showed that induced AF
is accompanied by a substantial increase (up to 80%) in atrial
pressure. In addition, it is well known that persistent AF, as
found in our patient population, is accompanied by a
significant dilation of the atria (3,22). Increased atrial
stretch during SR in the presence of various cardiac diseases,
however, could cause activation of the Erk cascade and may
induce changes in atrial refractoriness, thereby facilitating
atrial arrhythmias (23–25). Thus, activation of Erk1/Erk2
may occur prior to or simultaneously with the development
of AF in the setting of intraatrial pressure overload. In our
study, patients with PAF had similar levels of activated
Erk1 and Erk2 compared to patients with CAF. In addi-
tion, there was no correlation between Erk2 mRNA expres-
sion and AF duration. One can hypothesize, therefore, that
increased activation of Erk1/Erk2 induces atrial fibrosis and
thereby provides the pathophysiologic substrate that predis-
poses to the occurrence of AF.
Other signaling pathways may also contribute to the
development of structural atrial changes during AF. Partic-
ularly, stress-responsive kinases such as cJNK or p38-
Figure 3. A, Effect of ACE inhibitor therapy on Erk1 (upper
band) and Erk2 (lower band) activity during SR. Western blots
demonstrating activated Erk1/Erk2 in patients without (n 5 7)
and with ACE inhibitors (n 5 9). B, Densitometric quantification
of Western blots shown in A. Amounts of phospho-Erk1 and
phospho-Erk2 are shown as relative densitometric absorption
units. Asterisk: p , 0.05 versus ACE inhibitor treatment.
Figure 4. A, Western blots demonstrating differences in ACE
expression between patients with SR (n 5 7) and CAF (n 5 7).
No patient had received ACE inhibitors prior to surgery. B,
Densitometric quantification of the Western blots shown in A.
The ACE expression is shown as relative densitometric absorption
units. Asterisk: p , 0.01 versus SR.
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MAPK are associated with fibrogenesis (26–28). cJNK and
p38-MAPK are activated, for example, in response to
inflammatory cytokines, hypoxia, UV irradiation and Ang II
(26,27,29). Thus, Ang II may activate several intracellular
signal transduction pathways during AF, whereas cytokines
or adenosine triphosphate depletion seem not to be respon-
sible for structural changes in fibrillating atria (5,30). Acti-
vation of the Erk pathway alone might not be sufficient to
induce the full spectrum of fibrotic changes (28,31,32).
However, proliferation of fibroblasts, which is an elemental
feature in the development of cardiac fibrosis, is dependent
on the MEK-Erk cascade (11,33,34). But, the simultaneous
employment and cross-talk of parallel pathways may explain
the weak linear correlation between the expression of ACE,
MEK1/2, and Erk1/2.
In addition, alterations of Ang II-receptor expression
may occur during AF and modulate MAPK activity and
expression. An overexpression of the AT1-receptor (35–37)
could cause an amplification of the Ang II-dependent
signaling. Down-regulation of the AT1-receptor or up-
regulation of the AT2-receptor, as seen in patients with
terminal ventricular failure, could have an inhibitory effect
Figure 5. A, Immunostaining of atrial tissue with Erk1/Erk2 antibody in a patient with CAF. Erk1/Erk2 were found within interstitial
cells (arrows) and vascular endothelial cells (arrowhead; magnification 3120, reduced by 65%). B, Immunostaining with Erk1/Erk2
antibody in a patient with SR. Significantly less immunostaining was found within the tissue specimen (magnification, 3120, reduced by
65%). C, Intense intracellular immunostaining of myocytes with myoglobin antibody shows that reduced or missing intracellular
immunostaining with Erk1/Erk2 is not related to fixation artifacts (same specimen as in A; magnification 3120, reduced by 65%). D,
Masson trichrome stain in a patient with CAF. A prominent pericardial fibrotic layer (blue stain) extends from the pericardial surface deep
into the atrial interstitium. In addition, interstitial fibrosis is present coating individual myocytes (magnification, 3120, reduced by 65%).
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on the Erk-cascade (14,38,39). An up-regulation of AT2-
receptors due to an increased atrial pressure was described in
humans (40). Masaki et al. (41) ascertained that AT2-
receptor activation decreases the AT1-receptor mediated
ERK-activity by activation of ERK-phosphate 1. An in-
creased expression of AT2-receptor, therefore, may inhibit
the progression of interstitial fibrosis by decreasing Ang
II-induced proliferation of fibroblasts and matrix protein
accumulation (14,42). However, despite the demonstrated
down-regulation of AT1-receptors in failing hearts, recent
studies have also shown that the amounts of phosphorylated
Erk1/2 are not decreased in this setting (43,44). Further
studies are warranted to elucidate the regulation of Ang
II-receptor expression in patients with AF.
Atrial fibrosis and AF. Atrial fibrillation causes significant
electrophysiologic and structural changes in the atrial tissue
(3–6). Several studies have demonstrated that prolonged
episodes of AF are accompanied by a “tachycardia-induced
atrial myopathy” (3,6,10). In contrast to animal models of
pacing-induced AF, atrial biopsy specimens from patients
with persistent AF revealed interstitial fibrosis and vascular
degeneration of atrial myocytes (8). In the present study,
patients with AF showed atrial fibrosis and dilated atria that
have been reported by others (3,10,22). Whether all fibrotic
alterations of the atrial tissue are induced by AF itself is not
known. Li et al. (9) used a canine model to show that pacing
induced heart failure is associated with the development of
atrial fibrosis. In this model, atrial fibrosis resulted in
increased conduction heterogeneity favoring the inducibility
of AF. Atrial refractoriness, however, showed no changes.
Similarly to the animal experiments, spatial inhomogene-
ities of conduction were also demonstrated in the right and
left atria from patients with AF and mitral valve disease
(45). The hypothesis that atrial fibrotic changes are already
present in early phases of AF is supported by our findings
that tissue specimens from patients with PAF and CAF
showed similar amounts of activated Erk1/Erk2. Persis-
tently increased Erk activity over years during CAF, how-
ever, may cause progressive atrial fibrosis. The time period
of increased Erk activity and the amount of fibrotic tissue
may determine the difference between paroxysmal and
persistent AF.
Clinical implications. The present study provides evidence
that AF is associated with an increased expression of ACE
and increased amounts of activated Erk1/Erk2 in atrial
tissue. We could show that the level of an activated
Erk1/Erk2 is lower during treatment with ACE inhibitors.
It is of great interest to show in prospective studies whether
ACE inhibitor treatment influences the clinical course as
well as the morphologic appearance of the atria in patients
with AF. This is supported by results from Van Den Berg
et al. (46) who showed a beneficial effect of ACE inhibitor
treatment in patients with AF and heart failure. Further-
more, a clinical trial demonstrated that ACE inhibitor
therapy reduces the incidence of AF in patients with left
ventricular dysfunction after a myocardial infarction (47), a
finding that might be explained by an inhibition of the Erk
pathway as demonstrated in the present study.
Study limitations. Some potential limitations may have
influenced our results. All patients included in our study
underwent cardiac surgery and had coronary artery disease
or significant valve diseases. The pathophysiologic mecha-
nism of AF in lone AF patients may be different. Different
cardiac diseases, however, were distributed similarly within
the analyzed groups. The underlying heart disease had no
obvious impact on Erk1/Erk2 expression or activation. In
contrast to autopsy and animal studies, we examined only
tissue specimens from the right atrial appendage. Thus, no
comment can be made regarding the distribution of changes
in activated Erk1/Erk2 within the rest of the atria. cJun and
p38-MAPK expression was not determined. Increased ex-
pression of these MAPKs may contribute to the develop-
ment of atrial fibrosis during AF. Further studies are needed
to determine the impact of AF on atrial cJun and p38-
MAPK activity. Ang II tissue levels were not determined in
the study. The described increased expression of ACE,
therefore, may not necessarily result in enhanced Ang II
activity. The amount of activated Erk1/2, however, was
related to ACE expression. The extent of fibrosis was not
quantified. However, the differences in atrial fibrosis be-
tween patients with and without AF were strikingly evident.
CONCLUSIONS
To the best of our knowledge, the present study demon-
strates for the first time an increase in atrial expression and
activation of Erk1/Erk2 in patients with AF. Enhanced
activation of Erk1/Erk2 within interstitial cells, most likely
due to an activated angiotensin system, may explain the
presence of marked atrial fibrosis in association with AF.
These findings may have an important impact on the
treatment of AF with ACE inhibitors.
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